Cel The IMMPACT project aims to perform the clinical validation of a serum biomarker signature for the early diagnosis of pancreatic cancer. The biomarker signature is based on the world’s most advanced recombinant antibody microarray platform owned by Immunovia AB. The underlying technology is affinity proteomics. The biomarker signature hence exploits the body’s own detection network for the diagnosis of cancer. The initial retrospective clinical studies have confirmed that the biomarker signature can accurately separate pancreatic cancer patients from healthy individuals. The implication is that the signature, once validated by a robust method, has a very high potential for the short-term uptake into clinical practice. The European dimension of the project lies in the validation of the biomarker signature that will make it possible for the first time to accurately diagnose pancreatic cancer in an asymptomatic stage (I and II) when the cancer is resectable. The results of the project will help to build up evidence that pancreatic cancer can be detected at an early stage, thus laying the basis for the future implementation of screening programmes of population groups at risk. The project stems from the unmet clinical need for the early detection of PDAC. Pancreatologists need a reliable biomarker for the early diagnosis (yes/no) diagnosis of pancreatic cancer. The test should primarily indicate whether the patient has cancer, not if the patient has a high risk of getting cancer. The new biomarker signature will address those needs and allow Immunovia to benefit from the tremendous business opportunity. Immunovia’s business strategy is based on extensive efforts towards validating the new biomarker signature by retrospective and prospective clinical trials. The validation to be undertaken in the project will accelerate an international clinical uptake of Immunovia’s blood based-tests. The project is thus fully aligned with Immunovia’s business development strategy. Dziedzina nauki medical and health sciencesclinical medicineoncologyprostate cancermedical and health sciencesclinical medicinesurgerymedical and health sciencesclinical medicineoncologybreast cancermedical and health sciencesclinical medicineoncologycolorectal cancermedical and health sciencesclinical medicineoncologypancreatic cancer Program(-y) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Temat(-y) PHC-12-2014 - Clinical research for the validation of biomarkers and/or diagnostic medical devices Zaproszenie do składania wniosków H2020-SMEInst-2014-2015 Zobacz inne projekty w ramach tego zaproszenia Szczegółowe działanie H2020-SMEINST-2-2014 System finansowania SME-2 - SME instrument phase 2 Koordynator IMMUNOVIA AB Wkład UE netto € 4 244 969,00 Adres SCHEELEVAGEN 2 MEDICON VILLAGE 223 81 LUND Szwecja Zobacz na mapie MŚP Organizacja określiła się jako MŚP (firma z sektora małych i średnich przedsiębiorstw) w czasie podpisania umowy o grant. Tak Region Södra Sverige Sydsverige Skåne län Rodzaj działalności Private for-profit entities (excluding Higher or Secondary Education Establishments) Linki Kontakt z organizacją Opens in new window Strona internetowa Opens in new window Uczestnictwo w unijnych programach w zakresie badań i innowacji Opens in new window sieć współpracy HORIZON Opens in new window Koszt całkowity € 4 244 969,25
